Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

385 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The toxicity and efficacy of Nordic-FLOX regimen as adjuvant treatment of stage III colon cancer.
Demir L, Somali I, Oktay Tarhan M, Erten C, Ellidokuz H, Can A, Dirican A, Vedat Bayoglu I. Demir L, et al. Among authors: can a. J BUON. 2011 Oct-Dec;16(4):682-8. J BUON. 2011. PMID: 22331722
RESULTS: The probability of disease-free survival (DFS) at a median follow-up time of 29 months was 72%. Relapse was seen in 13 (24.5%) patients. ...CONCLUSION: Adjuvant treatment of stage III colon cancer with the Nordic-FLOX regimen can be an alternative regimen t …
RESULTS: The probability of disease-free survival (DFS) at a median follow-up time of 29 months was 72%. Relapse was seen in 13 (24.5 …
One-day DCF regimen in patients with metastatic gastric cancer.
Dirican A, Kucukzeybek Y, Tarhan MO, Somali I, Erten C, Demir L, Can A, Bayoglu IV, Akyol M, Ekinci N, Medeni M, Koyuncu B, Alacacioglu A. Dirican A, et al. Among authors: can a. Tumori. 2013 Mar-Apr;99(2):145-8. doi: 10.1177/030089161309900204. Tumori. 2013. PMID: 23748805
Treatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab?
Dirican A, Varol U, Kucukzeybek Y, Alacacioglu A, Erten C, Somali I, Can A, Demir L, Bayoglu IV, Akyol M, Yildiz Y, Koyuncu B, Coban E, Tarhan MO. Dirican A, et al. Among authors: can a. Asian Pac J Cancer Prev. 2014;15(12):4781-6. doi: 10.7314/apjcp.2014.15.12.4781. Asian Pac J Cancer Prev. 2014. PMID: 24998541 Free article.
Malignant epithelioid hemangioendothelioma progressing after chemotherapy and Interferon treatment: a case presentation and a brief review of the literature.
Demir L, Can A, Oztop R, Dirican A, Bayoglu V, Akyol M, Kucukzeybek Y, Erten C, Somali I, Tarhan MO. Demir L, et al. Among authors: can a. J Cancer Res Ther. 2013 Jan-Mar;9(1):125-7. doi: 10.4103/0973-1482.110386. J Cancer Res Ther. 2013. PMID: 23575093 Free article. Review.
Epithelioid hemangioendothelioma is a rare, low-grade malignant vascular tumour. It is frequently seen in the liver, but can occur in the lungs, bones, and other soft tissues. Although survival time might be reasonable in cases that can undergo liver transpla …
Epithelioid hemangioendothelioma is a rare, low-grade malignant vascular tumour. It is frequently seen in the liver, but can o …
385 results